SOPHiA GENETICS2022-03-16T14:48:05+00:00

Project Description

CEO
Jurgi Camblong

Sector
Diagnostics & Life Sciences

Location
Saint-Sulpice, Switzerland and Boston Massachusetts, US

Investment Stage
Growth

Investment status
Current

Year invested
2020

Endeavour Vision Deal Team
Damien Tappy
Meret Gaugler
Fernando Pacheco

Back to all companies

SOPHiA GENETICS

SOPHiA GENETICS’ AI-based platform helps healthcare professionals make sense of genomic and radiomic data while sharing their knowledge through the world’s largest network of institutions, supporting them in their decision-making to improve diagnosis and treatment of cancer and rare diseases. SOPHiA GENETICS’ solutions are democratising data-driven medicine, bringing precision medicine and targeted therapies to more patients in 85 countries.

The company completed its initial public offering in July, 2021, and is registered under the ticker Nasdaq:SOPH.

Read More

Learn More

Discover the SOPHiA DDM™️ Platform

Go to Top